A Network Pharmacology-Based Strategy For Predicting Active Ingredients And Potential Targets Of LiuWei DiHuang Pill In Treating Type 2 Diabetes Mellitus
Received 22 May 2019
Accepted for publication 27 September 2019
Published 28 November 2019 Volume 2019:13 Pages 3989—4005
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Sukesh Voruganti
Dan He,1 Jian-Hua Huang,1–3 Zhe-Yu Zhang,4 Qing Du,1 Wei-Jun Peng,4 Rong Yu,1,2 Si-Fang Zhang,4 Shui-Han Zhang,1,* Yu-Hui Qin1,*
1Hunan Academy of Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan 410013, People’s Republic of China; 2Hunan Key Laboratory of TCM Prescription and Syndromes Translational Medicine, Changsha, Hunan 410208, People’s Republic of China; 32011 Collaboration and Innovation Center for Digital Chinese Medicine in Hunan, Changsha 410013, People’s Republic of China; 4Department of Gastroenterology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Shui-Han Zhang; Yu-Hui Qin
Hunan Academy of Chinese Medicine, Hunan University of Chinese Medicine, No. 300 Xueshi Road, Hanpu Science Park, Changsha, Hunan 410013, People’s Republic of China
Email firstname.lastname@example.org; email@example.com
Background: Traditional Chinese medicine (TCM) formulations have proven to be advantageous in clinical treatment and prevention of disease. LiuWei DiHuang Pill (LWDH Pill) is a TCM that was employed to treat type 2 diabetes mellitus (T2DM). However, a holistic network pharmacology approach to understanding the active ingredients and the therapeutic mechanisms underlying T2DM has not been pursued.
Methods: A network pharmacology approach including drug-likeness evaluation, oral bioavailability prediction, virtual docking, and network analysis has been used to predict the active ingredients and potential targets of LWDH Pill in the treatment of type 2 diabetes.
Results: The comprehensive network pharmacology approach was successfully to identify 45 active ingredients in LWDH Pill. 45 active ingredients hit by 163 potential targets related to T2DM. Ten of the more highly predictive components (such as :quercetin, Kaempferol, Stigmasterol, beta-sitosterol, Kadsurenone, Diosgenin, hancinone C, Hederagenin, Garcinone B, Isofucosterol) are involved in anti-inflammatory, anti-oxidative stress, and the reduction of beta cell damage. LWDH Pill may play a role in the treatment of T2DM and its complications (atherosclerosis and nephropathy) through the AGE-RAGE signaling pathway, TNF signaling pathway, and NF-kappa B signaling pathway.
Conclusion: Based on a systematic network pharmacology approach, our works successfully predict the active ingredients and potential targets of LWDH Pill for application to T2DM and helps to illustrate mechanism of action on a comprehensive level. This study provides identify key genes and pathway associated with the prognosis and pathogenesis of T2DM from new insights, which also demonstrates a feasible method for the research of chemical basis and pharmacology in LWDH Pill.
Keywords: LWDH Pill, type 2 diabetes mellitus, T2DM, network pharmacology
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]